Target intelligence / Profile preview

Nicotinamide nucleotide transhydrogenase (NNT)

Target
NNT
Molecular classification
Enzyme (oxidoreductase), Mitochondrial membrane protein
01

Overview

Nicotinamide nucleotide transhydrogenase is an integral enzyme of the inner mitochondrial membrane that couples hydride transfer from NADH to NADP+ with proton translocation across the membrane. This process regenerates NADPH, which is essential for antioxidant defense and protecting mitochondrial and cellular components from oxidative damage. NNT plays a central role in cellular redox balance, particularly in tissues like adrenal glands, heart, kidneys, and fat. Its deficiency causes familial glucocorticoid deficiency, a rare disorder linked to adrenal insufficiency and increased oxidative stress. Structurally, it is a homodimeric protein complex with three main domains for substrate binding and proton transport. Research has not identified clinically approved drugs that directly modulate NNT activity, but its function is a key area of interest for mitochondrial biology and redox therapeutics.

Other names
NNTNAD(P) transhydrogenase, mitochondrialGCCD4
02

Mechanism of action

(Hypothetical) Modulate enzyme activity: drugs could increase or decrease NADPH regeneration or alter proton translocation. Antioxidant modulation: compounds might enhance ROS clearance via upregulating or mimicking NNT function.

03

Biological functions

NADP(H) regenerationRedox homeostasisAntioxidant defenseProton translocation across inner mitochondrial membraneRegulation of reactive oxygen species (ROS)Metabolism (coupling NADH oxidation to NADPH production)
04

Disease associations

Familial glucocorticoid deficiencyEndocrine (adrenal and thyroid gland) dysfunctionCardiometabolic disease (via oxidative stress)Aging-related diseases (due to impaired redox balance)Other mitochondrial diseases
05

Safety considerations

Genetic deficiency leads to adrenal failure and vulnerability to oxidative stressTargeting NNT therapeutically risks affecting global cellular redox homeostasis, which could compromise antioxidant protection and mitochondrial function
06

Interacting drugs

Direct NNT inhibitors/activators are not well-established in clinical use. Indirectly, drugs affecting mitochondrial redox balance (e.g., antioxidants, NADPH-dependent pathway modulators) may interact; however, no approved pharmaceuticals specifically target NNT.
07

Biomarkers

NNT gene mutation (for familial glucocorticoid deficiency)NADPH/NADP+ ratio (mitochondrial redox status)

Beyond the preview

Go deeper on Nicotinamide nucleotide transhydrogenase (NNT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicotinamide nucleotide transhydrogenase (NNT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call